Clearmind Medicine Appoints Chief of Global Impact
Ticker: CMND · Form: 6-K · Filed: Oct 27, 2025 · CIK: 1892500
Sentiment: neutral
Topics: management-change, press-release, foreign-private-issuer
TL;DR
Clearmind Medicine hires Mary-Elizabeth Gifford as Chief of Global Impact to boost US partnerships.
AI Summary
Clearmind Medicine Inc. announced on October 27, 2025, the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. This strategic hire aims to advance US partnerships and governmental engagement for the company.
Why It Matters
The appointment of a Chief of Global Impact suggests Clearmind Medicine is prioritizing strategic partnerships and governmental relations, particularly in the US, which could be crucial for its future growth and market access.
Risk Assessment
Risk Level: medium — The filing is a routine 6-K report, but the company operates in the pharmaceutical sector, which carries inherent regulatory and market risks.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- Mary-Elizabeth Gifford (person) — Appointed Chief of Global Impact
- October 27, 2025 (date) — Date of press release and filing
FAQ
What is the primary purpose of Mary-Elizabeth Gifford's appointment as Chief of Global Impact?
Mary-Elizabeth Gifford's appointment is to advance US partnerships and governmental engagement for Clearmind Medicine Inc.
What type of filing is this for Clearmind Medicine Inc.?
This is a Form 6-K filing, which is a Report of Foreign Private Issuer.
When was the press release regarding this appointment issued?
The press release was issued on October 27, 2025.
What is Clearmind Medicine Inc.'s SIC code?
Clearmind Medicine Inc.'s Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
Where is Clearmind Medicine Inc.'s principal executive office located?
Clearmind Medicine Inc.'s principal executive office is located at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
Filing Stats: 283 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2025-10-27 09:25:01
Filing Documents
- ea0262593-6k_clearmind.htm (6-K) — 12KB
- ea026259301ex99-1_clearmind.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-102378.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: October 27, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3